The N-terminal domain (NTD) and the ligand-binding domain (LBD) of the androgen receptor (AR) exhibit a ligand-dependent interaction (N/C interaction 
, is essential for LBD interaction. We demonstrate in the current study that AR 3)36 can be subdivided into two functionally distinct fragments: AR 3) 13 and AR 16) 36 . AR 3)13 does not directly interact with the AR LBD, but rather contributes to the transactivation function of the AR.NTD-AR.LBD complex. AR 16 , shows no affinity to the LBD. Within AR 16) 36 , amino acid residues in and flanking the 23 FxxLF 27 motif are demonstrated to modulate N/C interaction. Substitution of Q24 and N25 by alanine residues enhances N/C interaction. Substitution of amino acids flanking the 23 FxxLF 27 motif by alanines are inhibitory to LBD interaction.
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The androgen receptor (AR) is a member of the steroid receptor subgroup of the nuclear receptor family of transcription factors. Nuclear receptors have a modular structure, composed of a moderately conserved carboxyterminal ligand-binding domain (LBD) folded in 12 a-helices, a highly conserved central DNA-binding domain (DBD) and a nonconserved N-terminal domain (NTD). Most nuclear receptors contain two transactivation functions: AF-1 in the NTD, and AF-2 in the LBD. Ligandactivated nuclear receptors bind as homo-or heterodimers to hormone-response elements in the regulatory regions of their target genes. Together with coactivators, general transcription factors and RNA polymerase II, they form a stable transcription initiation complex [1] [2] [3] [4] .
Upon ligand binding, the LBD acquires a conformation that facilitates the interaction with coactivators. Best studied in this regard are the interactions with the p160 coactivators SRC1, TIF2/GRIP1 and ACTR/RAC3. The nuclear receptor interaction domains of p160 coactivators contain LxxLL motifs (NR boxes) which bind to a hydrophobic cleft in the agonist-activated LBD. Antagonists induce a different LBD conformation which inhibits the interaction with coactivators and enables the binding of corepressors [3, 5] .
P160 coactivators not only bind to the LBD, but also to the NTD [6, 7] . This interaction is independent of the NR boxes. As shown for the estrogen receptor a (ERa), simultaneous NTD and LBD binding by one coactivator can confer synergism of AF-1 and AF-2 activities, which might be necessary for optimal functioning [8] .
Like shown for other nuclear receptors, p160 coactivators can bind the AR LBD by their LxxLL motifs, and they interact with the AR NTD, independent of these motifs [9] [10] [11] . In contrast to AR AF1, which is strong, AF-2 needs overexpression of a p160 coactivator to become manifest [9, 10, [12] [13] [14] [15] . Many other proteins with known or unknown functions have been found to interact with the AR. An overview of AR-interacting proteins is presented in the AR mutations database (http://www.mcgill.ca/androgendb) [16] .
Previously, a ligand-dependent functional interaction between the AR subdomains NTD and LBD, has been described [17] [18] [19] . This N/C interaction might be intra-or intermolecular [15, [17] [18] [19] . In vitro pull-down experiments indicated that the AR N/C interaction is direct [11] . The AF-2 core domain in helix 12 of the AR LBD was shown to be involved in this interaction [11, 15] . In the AR NTD, two regions are involved in the functional interaction with the AR LBD: AR 3)36 , including the 23 
FxxLF
27 motif, and AR 370-494 , which encompasses a transactivation function and a presumed supplementary protein interaction domain [15, 20] . In the present study, AR 3)36 is subdivided into two fragments: AR 3)13 and AR 16) 36 , which are further characterized.
E X P E R I M E N T A L P R O C E D U R E S

Materials and plasmid construction
Dihydrotestosterone (DHT) was purchased from Steraloids (Wilton, NH, USA), R1881 (methyltrienolone) was from NEN (Boston, MA, USA).
Standard procedures were utilized for PCR and molecular cloning [21] . PCR products were inserted in pGEM-T Easy (Promega, Madison, WI, USA). All plasmids were sequenced to verify their correct construction. Primer sequences are shown in Table 1 . AR numbering corresponds to a length of 919 amino acids, as employed by The Androgen Receptor Gene Mutations Database (http:// www.mcgill.ca/androgendb).
Yeast expression constructs
pGalAD-AR.NTDwt (AR ), originally derived from the yeast expression vector pACT2 (Clontech, Palo Alto, CA, USA), and pGalDBD-AR.LBD (AR 661-919 ), originally derived from the yeast expression vector pGBT9 (Clontech), were previously described as AR.N8 (high) and pGAL4(DBD)AR(LBD), respectively [15, 18] . pGalAD-AR.NTDD1-13 was obtained by exchange of a 75-bp SmaI fragment of pGalAD-AR.NTDwt with a corresponding fragment derived from a PCR product synthesized with primers pr14 and pr1B, utilizing pSVAR 0 [22] as template. pGalAD-AR.NTDD3-36 was obtained by excision of a 117-bp SmaI fragment from pGalAD-AR.NTDwt. For generation of pGalAD-AR.NTD23/27RR, pGalAD-AR.NTD30/33RR, pGalAD-AR.NTD24/25AA and pGalAD-AR.NTD26/27AA, a 117-bp SmaI fragment of pGalAD-AR.NTDwt was exchanged with corresponding fragments containing the indicated mutations, which were obtained by PCR on the template pGalAD-AR.NTDwt utilizing primer G4AD1 (Clontech) in combination with one of the following oligonucleotides: pr23/27RR, pr30/ 33RR, pr24/25AA, and pr26/27AA (mutated codons are underlined in Table 1 ).
The AR peptide construct pGalAD-AR 2-36 was obtained by insertion of a 117-bp BamHI/EcoRI fragment, which was synthesized by PCR on the template pSVAR 3 [23] , utilizing primers pr2-36sense and pr2-36antisense, into the corresponding sites of pACT2 (Clontech). All other pGalADARpeptide constructs were generated by BamHI/EcoRI in frame insertion of double-stranded oligonucleotides into the corresponding sites of pACT 2 (30/31AA) . Oligonucleotides for these AR peptide expression constructs were: pr1-14sense, pr1-14antisense, pr16-36sense, pr16-36antisense, pr17-32sense, pr17-32antisense, pr24-39sense, and pr24-39antisense. Primers pr18/19AA, pr20/21AA, pr22A, pr24/25AA, pr26/27AA, pr28/29AA, and pr30/ 31AA sense and antisense oligonucleotides were modified pr17-32 sense and antisense oligonucleotides, containing GCTGCA (sense) and TGCAGC (antisense) as two adjacent alanine codons at the indicated positions.
Mammalian cell expression constructs
pMMTV-LUC, pSVAR.NTDwt (AR 1)503 ) [originally described as pSVAR(TAD 1)494 )] and pSVAR.DBD.LBD (AR 537)919 ) (originally described as pSVAR-104) were previously published [18, 23, 24] . Insertion of a 1.9-kb HindIII fragment from pSVAR 3 in HindIII digested pGAD 424 (Clontech) yielded pGAD 3 . pGAD 3 .NTDD3-13 Table 1 . Primers for construction of plasmids.
Primer name
Primer sequence 
Pull-down constructs
For pSVAR.NTDwt and pSVAR.NTDmutant see Mammalian cell expression constructs. pCMV-GST-AR.LBD (AR 664)919 ) was generated as follows: pGEX-2TK-CHB was obtained by BamHI/EcoRI in frame insertion of a double-stranded oligonucleotide in the corresponding sites of pGEX-2TK (Amersham Biosciences, Uppsala, Sweden). Oligonucleotides were PDsense and PDantisense. Insertion of the AR.LBD ClaI/BglII fragment from pAR 34 [23] into the corresponding sites of pGEX-2TK-CHB yielded pGST-AR.LBD. Insertion of the AR LBD BamHI/SalI fragment of pGST-AR.LBD into the corresponding sites of pCMV-GST [25] yielded pCMV-GST-AR.LBD.
Yeast growth, transformation and b-galactosidase assay
Yeast strain Y190 (Clontech), containing an integrated Gal4 driven UAS GAL1 -lacZ reporter gene, was utilized for twohybrid experiments. Yeast cells were grown in the appropriate selective medium (0.67% w/v yeast nitrogen base without amino acids, 2% w/v glucose, pH 5.8), supplemented with the required amino acids. Yeast transformation was carried out according to the lithium acetate method [26] . A yeast liquid b-galactosidase assay was performed to quantify the interaction of GalAD-AR.NTDwt, GalAD-AR.NTDmutant and GalAD-ARpeptide proteins with GalDBD-AR.LBD. In short, stationary phase cultures of Y190 yeast transformants grown in selective medium were diluted in the same medium supplemented with 1 lM DHT or without hormone, and grown until an OD 600 between 0.7 and 1.2. Next, b-galactosidase activity was determined as described previously [18] .
Mammalian cell culture, transfection, and luciferase assay
Chinese hamster ovary (CHO) cells were maintained in DMEM/F12 culture medium, supplemented with 5% dextran-coated charcoal-treated fetal bovine serum (Life Technologies, Gaithersburg, MD, USA). Cells were plated in 24-well plates at a density of 2 · 10 4 cells per well, in a total volume of 0.5 mL. Cells were transfected with MMTV-LUC reporter plasmid (50 ngAEwell ), supplemented with pTZ19 as carrier DNA to a total amount of 300 ngAEwell )1 , utilizing 0.5 lL FuGENE transfection reagent (Roche Inc., Mannheim, Germany) per well. After overnight incubation with or without 1 nM R1881, cells were harvested and luciferase measurement was performed as described previously [27] .
Protein extraction and Western blot analysis
Yeast protein extracts were obtained by direct lysis of yeast cells in 2 · SDS gel-loading buffer by a freeze/thawing cycle and boiling, according to Sambrook and Russell (2001) [21] . Western blot analysis for detection of GalAD fusion proteins was performed as previously described, utilizing a GAL4AD monoclonal antibody (Clontech) [18] .
CHO cells were plated at a density of 1.5 · 10 6 cells per 80 cm 2 flask and the next day were transfected with 1 lg pSVAR.NTDwt or pSVAR.NTDmutant, utilizing 12 lL FuGENE transfection reagent. After overnight incubation, cells were harvested by scraping in 1 mL NaCl/P i and centrifugation (5 min, 800 g). Protein extracts were obtained by lysis of the pelleted cells in 60 lL lysis buffer A (20 mM Tris, 1 mM EDTA, 0.1% Nonidet P40, 25% glycerol, 20 mM Na-molybdate, pH 6.8), with addition of 0.3 M NaCl, followed by three cycles of freeze/thawing and centrifugation (10 min at 400 000 g). Western blot analysis for detection of AR.NTD proteins was performed as previously described, utilizing AR antibody SP061 [18, 28] .
Pull-down assay
CHO cell plating, transfection, harvesting, and protein extraction were carried out as described in the previous section, except that 3 lg pCMV-GST-AR.LBD and 1 lg pSVAR.NTDwt or pSVAR.NTDmutant were utilized, and that transfection and cell lysis were in the absence or presence of 100 nM R1881. Protein lysate (5 lL) was directly applied on a 10% SDS/PAGE gel (10% input). Lysate (50 lL) was mixed with 150 lL buffer A, with or without 100 nM R1881, and rotated for 5 h at 4°C with 25 lL glutathione-agarose beads (Sigma-Aldrich, Deisenhofen, Germany). Next, agarose beads were washed five times with buffer A supplemented with 0.1 M NaCl with or without 100 nM R1881, boiled in 30 lL Laemmli sample buffer and 25 lL supernatant was separated over a 10% SDS/PAGE gel. After Western blotting, visualization of input and precipitated AR.NTD proteins was carried out as described above.
R E S U L T S Systems for detection of androgen receptor N/C interaction
The ligand-dependent interaction between AR NTD and AR LBD, N/C interaction, was studied in yeast and mammalian in vivo protein interaction systems, and in pull-down assays. In the yeast two-hybrid system, vectors encoding the Gal4 transactivating domain (GalAD) fused to AR NTDwt, AR NTDmutant or ARpeptides derived from AR NTD, were transfected to a yeast strain, which expressed the Gal4 DNA-binding domain (GalDBD) linked to AR.LBD (Fig. 1A) . Upon incubation with DHT, N/C interaction mediated the expression of an integrated UAS GAL1 -lacZ reporter gene, which was assessed in a b-galactosidase assay. Note that in this assay the transactivating function is provided by both AR NTD and GalAD.
In the mammalian protein interaction system, vectors encoding wild type or mutated AR NTD, and AR DBD-LBD were cotransfected to CHO cells (Fig. 1B) . R1881-induced activity of a transiently transfected androgen-inducible MMTV promoter was assessed in a luciferase assay. Note that in this assay the transactivating function is solely contributed by AR NTD.
In pull-down assays the fusion protein GST-AR.LBD and wild type or mutated AR.NTD proteins were transiently expressed in CHO cells. (Fig. 2A) . Deletion of the N-terminal 13 amino acids (GalAD-AR.NTDD1-13) resulted in a slightly diminished (approximately 20%) N/C interaction. Because GalAD-AR.NTDD1-13 was expressed at a higher level than GalAD-AR.NTDwt (Fig. 2C) , the decrease of AR N/C interaction caused by AR 1-13 deletion might actually be more than observed.
Similar to the yeast assay, in the mammalian protein interaction assay, deletion of AR completely prevented N/C interaction (Fig. 2B) . A much more pronounced effect of AR 3)13 deletion on N/C interaction was observed as compared to the yeast assay. The approximately 90% drop in activity is indicative of an important role of AR 3)13 in N/C interaction. The diminished interaction was not due to a lower expression level of AR.NTDD3-13. In fact, AR.NTDD3-13 expression was higher than AR.NTDwt expression (Fig. 2C) .
To investigate whether AR 3)13 directly binds to AR LBD, pull-down experiments were carried out. The results are presented in Fig. 3 . In the absence of ligand, none of the AR NTD proteins showed LBD interaction. However, in the presence of ligand, both AR.NTDwt and AR.NTDD3-13 bound to AR LBD with similar affinity (Fig. 3) . In contrast, AR.NTDD3-37 did not interact.
AR 2)14 cannot autonomously interact with the androgen receptor LBD
To substantiate the modulating role of AR 2)14 in N/C interaction, as suggested by the experiments described above, the individual peptides AR 2)36 , AR 2)14 and AR 16)36 coupled to GalAD (Fig. 4A) were assayed in the yeast protein interaction system (Fig. 4B) . No substantial interaction with AR.LBD was found for GalAD-AR 2)14 . Activity was retained for approximately 60% in the GalAD-AR 16)36 /AR.LBD complex. Because the GalAD-AR 2)36 expression level was lower than that of GalAD-AR 16)36 (Fig. 4C) , the actual difference in activity between GalAD-AR 2)36 and GalAD-AR 16)36 , might be larger. 30 
Analysis of
VREVI
34 in androgen receptor N/C interaction Prediction programs of protein secondary structures (see http://npsa-pbil.ibcp.fr) indicated a long a-helical structure for AR 20) 34 . A helical wheel drawing of this region predicted an amphipathic character of this helical structure (Fig. 5A) [29] . At positions 15 and 37, the putative a-helix is flanked by proline residues. Within the helix, two candidate FxxFF protein interaction motifs (F is any hydrophobic amino acid residue and x is any amino acid residue) are present: motif linked to GalAD (Fig. 5B) . As expected, in the yeast protein interaction system, ligand-dependent interaction with AR LBD could easily be detected for GalAD-AR [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . However, the interaction was weak for GalAD-AR [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] ( Fig. 5C ). Low activity was not due to decreased protein expression (Fig. 5D) . In a complementary yeast protein interaction experiment, the 30 
34 motif in GalAD-AR.NTDwt was modified by substitution of two hydrophobic amino acids by arginine residues, resulting in GalAD-AR.NTD30/33RR. These substitutions might cause steric hindrance in the interaction with the AR LBD surface, change the charge and disrupt the proposed amphipathic a-helical structure of AR 16)36 . GalAD-AR.NTD23/27RR was utilized as control. Substitution of V30 and V33 partially reduced the interaction, whereas the F23R,F27R mutation completely abolished the interaction (Fig. 6A) . Expression levels of GalAD-AR.NTDwt and GalAD-AR.NTD30/33RR were similar (Fig. 6C) .
Results obtained in the mammalian protein interaction system, utilizing the AR.NTD30/33RR mutant and AR.NTD23/27RR, were essentially identical to the observations made in the yeast system (Fig. 6B) . A partial inhibition of AR N/C interaction was observed for AR.NTD30/33RR, and an almost complete inhibition for AR.NTD23/27RR.
Pull-down experiments confirmed and extended the in vivo protein interaction experiments (Fig. 6D) . AR N/C interaction was diminished due to 30/33RR substitutions, and completely abolished by 23/27RR substitutions. Amino acid residues flanking F23, L26 and F27 modulate androgen receptor N/C interaction To study in more detail the role of 24/25QN in the 23 
FQNLF
27 motif in AR N/C interaction, these amino acids were substituted by 24/25AA. In both the yeast and mammalian protein interaction assay, GalAD-AR.NTD24/25AA and AR.NTD24/25AA formed even more active complexes with AR LBD than with wild-type AR NTD (Fig. 7A,B ) (note the low expression levels of the 24/25AA mutants in both systems; Fig. 7C ). As expected, AR.NTD26/27AA was incapable to interact with AR.LBD.
To extend these findings, an alanine scan was carried out for peptide GalAD-AR [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] (Fig. 8A) . Results of the yeast protein interaction assay are shown in Fig. 8(B) . Substitution of amino acids 23, 26 and 27 completely abolished interaction with GalDBD-AR.LBD and alanines at positions 24 and 25 increased the interaction capacity. All alanine substitutions of amino acids flanking 23 FQNLF 27 reduced the binding to AR LBD. Most prominent inhibitory effects were found for amino acid residues directly flanking 23 FQNLF 27 . Note that expression levels of the peptide constructs were similar (Fig. 8C) . (Figs 2 and 4) . Pulldown experiments provided evidence that AR 3)13 does not directly interact with AR LBD (Fig. 3) . On first sight, conflicting results were obtained in the yeast and mammalian protein interaction assays (Fig. 2) . In the yeast assay, reporter gene activity, which monitored the N/C interaction, was partly reduced by AR 3)13 deletion, whereas in the mammalian assay almost all reporter gene activity was lost. The most obvious difference between both assays is the coupling of AR.NTD to GalAD in the yeast assay, and the absence of a second transactivation domain linked to AR NTD in the mammalian assay. The latter assay completely depends on the intrinsic transactivating function of AR NTD and thus does not allow discrimination between loss of AR.NTD-AR.LBD binding and loss of AR.NTD transactivating function. In the yeast assay, loss of transactivation function of AR NTD mutants, which retain AR LBD interacting capacity, like AR.NTDD3-13, will be masked by the GalAD transactivating function. So, AR 3)13 is not essential but rather modulates N/C interaction, most probably by affecting the transactivation function of AR.NTD. Alternative explanations might be induction of a more favorable NTD conformation or stabilization of the in vivo N/C interaction, which are not reflected in the pull-down assays and peptide interaction experiments. Unfortunately, the primary structure and the predicted secondary structure of AR 3)13 do not give a clue to a more precise description of its function (data not shown). However, the fact that, between species, AR 3)13 is one of the most conserved regions of AR NTD, underscores a presumed important role in AR function [32] .
D I S C U S S I O N
The second domain that was studied, AR 16)36 , is essential in N/C interaction. The predicted structure indicated that AR 16)36 can fold in a remarkably long amphipathic a-helical structure, suggesting an important protein interaction interface [29] . AR 16)36 contains two FxxFF putative protein interaction motifs: 23 
FxxLF
27
, which was found to be pivotal for direct N/C interaction [20, this study], and 30 VxxVI 34 ( Figs 5 and 6 ). The latter sequence modulates N/C interaction. Amino acid residues in this sequence might contribute to the stability of the predicted a-helix. Alternatively, they might make additional contacts to the LBD surface. This is also true for other amino acid residues flanking the 23 
FxxLF
27 motif (Fig. 8) . Remarkably, substitution of Q24 and N25 by alanines increased N/C interaction (Figs 7 and 8) .
The AR FxxLF motif shows similarities to LxxLL motifs [5, 33, 34 ] present in nuclear receptor interaction domains (NR boxes) of p160 coactivators. LxxLL motifs are essential in the interaction with LBDs [33] . They bind to a hydrophobic cleft in nuclear receptor LBDs, which is marked by a charged clamp composed of a highly conserved lysine and glutamate residue in helix 3 and helix 12 of the LBD, respectively (K720 and E897 in AR) [35] [36] [37] . AR K720 and E897 are both involved in the ligand-dependent interaction between AR LBD and the coactivator TIF2 [9, 11, 15] . However, in the FxxLFmediated AR N/C interaction, E897 is essential, but K720 can be replaced by many other amino acids, without affecting N/C interaction [9, 11, 15, 38] . So, the AR N/C interaction is similar, but not identical, to LxxLL-mediated coactivator-LBD interaction.
The 3D structures of agonist bound LBD/LxxLL peptide complexes of several nuclear receptors have been elucidated, and interactions of the peptide backbone and its amino acid side chains with the LBD surface have been identified [5, 36, 37, 39] . It is presumed that upon binding to the LBD surface, the LxxLL motif adapts a short a-helical structure, which is stabilized by interaction with the charged clamp [5, 36, 37] . The first and last leucine residue in the LxxLL motif enter the hydrophobic cleft in the LBD, and directly contact amino acid residues within the cleft. The variable amino acids (xx) in the LxxLL motif point away from the cleft and seem not to interact directly with the LBD surface. Structural data for AR.LBD/LxxLL peptides are not available but, because AR.LBD/coactivator interaction also depends on K720 and E897, it might be predicted that they will be similar to LBD/LxxLL peptide complexes studied so far [9, 11, 15] . Because K720 is not essential for AR The LxxLL-like motifs LxxIL, FxxLL, and L/IxxI/VI, have been found in LBD binding coactivators or corepressors [40] [41] [42] [43] . FxxLF motifs that are able to contact AR LBD, have only been found in AR NTD and most recently in the AR coactivators ARA54 and ARA70, suggesting a specific role of these motifs in AR function [44] [45] [46] [47] . The increasing number of proteins found to interact with the AR LBD raises the question of the physiological relevance of the many interactions. It remains to be established whether all interactions take place in living cells under physiological conditions, whether interactions with different proteins are simultaneous or consecutive events, and which interactions are most stable and most specific. Recently, a start has been made to identify factors, including the AR, present in the transcription initiation complex of the prostate specific antigen enhancer/promoter, using chromatin immunoprecipitation (ChIP) [48] . Another question concerns the interaction of AR 16)36 with other proteins. One candidate might be the TFIID TATA box-binding protein associated factor 31, TAF II 31 , which has been found to interact with FxxFF motifs in acidic transcription activation domains of p65 (nuclear factor-kappa B), VP16, p53 and related proteins [31, [49] [50] [51] .
AR NTD has previously been proposed to accommodate more than one AR LBD interacting domain [9, 15, 20] [9] . However, peptides containing these motifs were unable to interact with AR LBD in the yeast protein interaction assay, excluding their role as a second autonomous interaction motif in AR NTD (data not shown). N/C interaction is not unique for the AR, but has also been described for other nuclear receptors. ERa ligand-dependent direct N/C interaction has been demonstrated, which was disrupted by amino acid substitutions that affect receptor function [52, 53] . The ERa N/C interaction could be induced by the agonist estradiol (E 2 ), but not by the antagonist ICI164 384 [53] . Recently, it was found that the ERa N/C interaction was required for SRC-1-mediated synergism between AF-1 and AF-2 function [8, 53] . The progesterone receptor (PR) showed direct N/C interaction in the presence of agonist R5020, but not in the presence of antagonist RU486 [54] . LxxLL motifs in the PR-B form were most probably not involved, because the shorter PR-A form, lacking these motifs, also showed N/C interaction [55] .
The role of the N/C interaction in full-length AR function is not well understood. Ligand-dependent AR N/C interaction affects ligand dissociation [11, 20, 56] . Whether this is a direct or an indirect effect is unknown. Disruption of the N/C interaction by mutation of the 23 FxxLF 27 motif has a limited effect on full length AR transactivation function [20, Steketee, unpublished observation] . However, several AR LBD mutants with reduced or completely abolished N/C interaction have been found in androgen insensitivity patients [11, 56, 57] . Additionally, both N/C interaction and the transactivating function of the AR prostate cancer mutant T877A can be induced by natural low affinity ligands like progesterone or E 2 or the AR antagonist cyproterone acetate [18] .
In conclusion, we propose that AR 3)36 is involved in a dynamic sequence of protein interaction events, including N/C interaction, in regulation of AR function. Detailed knowledge on the role of the AR N/C interaction would require the elucidation of its function under more physiological conditions, including the study of mouse models carrying AR mutants defective in N/C interaction.
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